Amarin Corp Plcuk (AMRN) Net Income towards Common Stockholders (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Net Income towards Common Stockholders of -$10.5 million for Q1 2026, up 33.03% YoY from -$7.9 million in Q1 2025, and down 758.82% sequentially from -$1.2 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting -$10.5 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 33.03% year-over-year to -$10.5 million; the TTM figure through Mar 2026 stood at -$33.6 million (up 61.77% YoY), while the FY2025 annual figure was -$38.8 million, up 52.79% from the prior year.
- Net Income towards Common Stockholders fell to -$10.5 million in Q1 2026, from -$1.2 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for AMRN reached as high as $1.5 million in Q2 2024 and fell as low as -$70.0 million in Q2 2022.
- The 5-year median for Net Income towards Common Stockholders is -$14.1 million (2025), against an average of -$17.4 million.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 1841.14% — and 2024, when it surged 108.67%.
- A 5-year view of Net Income towards Common Stockholders shows it stood at $856000.0 in 2022, then plunged by 775.35% to -$5.8 million in 2023, then slumped by 741.0% to -$48.6 million in 2024, then soared by 97.48% to -$1.2 million in 2025, then tumbled by 758.82% to -$10.5 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$10.5 million, -$1.2 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 47.33 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 1.65 |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | -10.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.51 Mn |
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -7.74 Mn |
| Jun 30, 2025 | -14.14 Mn |
| Mar 31, 2025 | -15.70 Mn |
| Dec 31, 2024 | -48.62 Mn |
| Sep 30, 2024 | -25.13 Mn |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | -9.95 Mn |
| Dec 31, 2023 | -5.78 Mn |
| Sep 30, 2023 | -19.31 Mn |
| Jun 30, 2023 | -17.56 Mn |
| Mar 31, 2023 | -16.46 Mn |
| Dec 31, 2022 | 856,000.00 |
| Sep 30, 2022 | -5.14 Mn |
| Jun 30, 2022 | -69.96 Mn |
| Mar 31, 2022 | -31.56 Mn |
| Dec 31, 2021 | 14.70 Mn |
| Sep 30, 2021 | -13.15 Mn |
| Jun 30, 2021 | 7.81 Mn |